Hercules Capital Stock (NYSE:HTGC), Trade Ideas

Hercules Capital

Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.

Long Ideas

News

Markets

Media

Trading Ideas

HTGC

JEPI

TOST

On CNBC’s &#34;Halftime Report Final Trades,&#34; Jenny Harrington of Gilman Hill Asset Management named  Hercules Capital, Inc. (NYSE: HTGC)  as her 

General Motors, Hercules Capital, Toast And More: CNBC&#39;s &#39;Final Trades&#39;

Penny Stocks

Small Cap

Intraday Update

Movers

ADEA

AHCO

AMRS

AMSC

ARCT

AXGN

BGLC

BNOX

BSFC

BURU

BYND

CECO

CHGG

COMP

CRDF

CRSP

DCGO

DDOG

DRUG

DTSS

ESGL

EVBG

FIVN

FPAY

GLBE

GPCR

GRRR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HLIO

ICUI

IHRT

INFI

INGR

MNKD

NVAX

OLPX

PLUS

PMTS

PRZO

PTRA

PWSC

QTRX

RGTI

SAFE

SEAC

SKYT

STRL

SVFD

SWIM

TLRY

TWKS

VTGN

VVOS

Gainers


	Nuburu, Inc.  (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser technology.


Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

CTRA

MRVI

UPST

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

RingCentral, Alteryx, International Flavors &amp; Fragrances And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Hercules Capital Inc

JMP Securities analyst Devin Ryan maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Market Outperform and raises the price target from $19 to $20.

Price Target

Analyst Ratings

JMP Securities Maintains Market Outperform on Hercules Capital, Raises Price Target to $20

Wells Fargo analyst Finian O'Shea maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $19.5 to $20.

Wells Fargo Maintains Overweight on Hercules Capital, Raises Price Target to $20

Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $21 to $21.5.

Piper Sandler Maintains Overweight on Hercules Capital, Raises Price Target to $21.5

Keefe, Bruyette &amp; Woods analyst Paul Johnson maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Market Perform and raises the price target from $18 to $19.

Keefe, Bruyette & Woods Maintains Market Perform on Hercules Capital, Raises Price Target to $19

Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.51 by 1.96 percent. This is a 4.17 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $121.553 million which beat the analyst consensus estimate of $119.016 million by 2.13 percent. This is a 15.67 percent increase over sales of $105.090 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Hercules Capital Q1 2024 GAAP EPS $0.50 Misses $0.51 Estimate, Sales $121.553M Beat $119.016M Estimate

Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) reported quarterly earnings of $0.50 per share which met the analyst consensus estimate. This is a 4.17 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $121.60 million which beat the analyst consensus estimate of $119.02 million by 2.17 percent. This is a 15.71 percent increase over sales of $105.09 million the same period last year.

Hercules Capital Q1 EPS $0.50, Inline, Sales $121.60M Beat $119.02M Estimate

SynOx Therapeutics Limited (&quot;SynOx&quot; or the &quot;Company&quot;), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a&nbsp;$35m&nbsp;loan facility with Hercules Capital, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) (&quot;Hercules&quot;).

Synox Therapeutics Secures Up To $35M Debt Financing With Hercules Capital To Progress Development And Commercialization Of Emactuzumab

In the latest quarter, 6 analysts provided ratings for Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Hercules Capital, revealing an average target of $18.92, a high estimate of $21.00, and a low estimate of $17.50. This upward trend is apparent, with the current average reflecting a 4.53% increase from the previous average price target of $18.10.
<img src="https://www.benzinga.com/files/images/story/2024/1712772040_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Hercules Capital by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ryan Lynch</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Timothy O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Casey Alexander</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$17.50</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hercules Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hercules Capital compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hercules Capital's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Hercules Capital's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HTGC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hercules Capital analyst ratings.</a>
<h2>Delving into Hercules Capital's Background</h2>
Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
<h3>Unraveling the Financial Story of Hercules Capital</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Hercules Capital showcased positive performance, achieving a revenue growth rate of 64.59% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Hercules Capital's net margin excels beyond industry benchmarks, reaching 86.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hercules Capital's ROE excels beyond industry benchmarks, reaching 6.96%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.56%, the company showcases effective utilization of assets.
Debt Management: Hercules Capital's debt-to-equity ratio is below the industry average. With a ratio of 0.87, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Hercules Capital

Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $20 to $21.

Piper Sandler Maintains Overweight on Hercules Capital, Raises Price Target to $21

JMP Securities analyst Devin Ryan maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Market Outperform and raises the price target from $18 to $19.

JMP Securities Maintains Market Outperform on Hercules Capital, Raises Price Target to $19

Monday marks the last chance for investors to receive the next dividend payout from Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>). 
<h3>What's Happening</h3>
The company announced on Tuesday that it would pay shareholders a quarterly dividend of 40 cents per share. On Tuesday, Hercules Capital will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 40 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Tuesday. Shareholders who own HTGC as of the end of Monday's session are eligible to receive the 40 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on March 06, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
To stay up-to-date with the companies that are announcing their dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Dividends

Hercules Capital's Ex-Dividend Date Is Tuesday, Here's What You Need To Know

In the preceding three months, 5 analysts have released ratings for Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.2, a high estimate of $20.00, and a low estimate of $17.00. This upward trend is evident, with the current average reflecting a 2.08% increase from the previous average price target of $17.83.
<img src="https://www.benzinga.com/files/images/story/2024/1708099223_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Hercules Capital among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Timothy O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Casey Alexander</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$17.50</td>
<td>-</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Vilas Abraham</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$17.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hercules Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hercules Capital compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Hercules Capital's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HTGC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hercules Capital analyst ratings.</a>
<h2>About Hercules Capital</h2>
Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
<h3>Hercules Capital's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Hercules Capital's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -29.4%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 54.32%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.73%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Hercules Capital's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.85%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Hercules Capital's debt-to-equity ratio stands notably higher than the industry average, reaching 0.99. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Hercules Capital Analyst Ratings

Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.50 by 12 percent. This is a 19.15 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $122.60 million which beat the analyst consensus estimate of $117.48 million by 4.36 percent. This is a 22.37 percent increase over sales of $100.19 million the same period last year.

Hercules Capital Q4 EPS $0.56 Beats $0.50 Estimate, Sales $122.60M Beat $117.48M Estimate

Record Q4 2023 Total Investment Income of $122.6 Million, an Increase of 22.4% Year-over-Year
Record Q4 2023 Net Investment Income "NII" of $86.0 Million, or $0.56 per Share, an Increase of 38.5% Year-over-Year
Record Full-Year 2023 Total Investment Income of $460.7 Million, an Increase of 43.2% Year-over-Year
Record Full-Year 2023 Net Investment Income "NII" of $304.0 Million, an Increase of 61.7% Year-over-Year
Record Full-Year 2023 Total Gross Fundings of $1.6 billion, an Increase of 9.1% Year-over Year
Inclusive of the Adviser Funds Managed by Hercules Adviser LLC, its Wholly-owned Subsidiary, Hercules had over $1.0 Billion of Available Liquidity as of Year End
Q4 2023 NII Provides 140% Coverage of the Base Cash Distribution
Announced a New Supplemental Cash Distribution for 2024 of $0.32 per Share, Payable over Four Quarters
Undistributed Earnings Spillover of $125.6 Million, or $0.80(1) per Ending Shares Outstanding
Approximately $4.2 Billion of Assets Under Management, an Increase of 15.3% Year-over-Year(2)
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.htgc.com%2F&amp;esheet=53897160&amp;newsitemid=20240215172753&amp;lan=en-US&amp;anchor=Hercules+Capital%2C+Inc.&amp;index=1&amp;md5=66f9443380fa97433f2c16dc54bc2bad">Hercules Capital, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2023. The earnings release can be accessed at Hercules' Investor Relations website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.htgc.com%2Ffinancial-information%2Ffinancial-results&amp;esheet=53897160&amp;newsitemid=20240215172753&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.htgc.com%2Ffinancial-information%2Ffinancial-results&amp;index=2&amp;md5=fe3ac4b55e183694e7ea621ed9c0d293">https://investor.htgc.com/financial-information/financial-results</a>.
Footnotes:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.82 per Weighted Average Shares Outstanding</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Assets under management includes assets managed by Hercules Capital and its Adviser Subsidiary</td>
</tr>
</tbody>
</table>
</figure>

HCXY

Hercules Capital Reports Q4 And FY23 Financial Results; Q4 2023 Total Investment Income Of $122.6M; Q4 2023 Net Investment Income Of $86M, Or $0.56 Per Share

AGIO

ALKS

ALLT

ALNY

AMAT

AORT

APPN

ARCH

ATRC

AUPH

BJRI

BLZE

BPMC

CBRE

CGNX

CLBT

CMBM

COHU

COIN

CORT

CRBG

CROX

CWST

DASH

DKNG

DNOW

EDRY

ELME

EPAM

GLOB

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HOUS

IDCC

IRDM

IREN

IRWD

ITGR

JMIA

KELYA

KELYB

KNSL

LBTYA

LECO

Laboratory Corporation Of America Holdings

MERC

MTRN

MYTE

NSIT

NVMI

OPEN

ORAN

OTLY

PACB

PCOR

PDFS

PENN

PRAA

PRTA

RARE

RELX

ROKU

RPRX

Earnings Scheduled For February 15, 2024

Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here's what investors need to know before the announcement.
Analysts estimate that Hercules Capital will report an earnings per share (EPS) of $0.50. 
Hercules Capital bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 1.43% drop in the share price the next day.
Here's a look at Hercules Capital's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.49</td>
<td>0.46</td>
<td>0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.52</td>
<td>0.53</td>
<td>0.48</td>
<td>0.47</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.43%</td>
<td>3.92%</td>
<td>4.47%</td>
<td>7.69%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707933740_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Hercules Capital were trading at $17.45 as of February 13. Over the last 52-week period, shares are up 16.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HTGC/earnings">To track all earnings releases for Hercules Capital visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Hercules Capital

Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.8, a high estimate of $18.50, and a low estimate of $17.00. This current average represents a 0.17% decrease from the previous average price target of $17.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1706558432_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Hercules Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Casey Alexander</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Neutral</td>
<td>$17.50</td>
<td>-</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Vilas Abraham</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$18.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hercules Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hercules Capital compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Hercules Capital's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hercules Capital's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HTGC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hercules Capital analyst ratings.</a>
<h2>Unveiling the Story Behind Hercules Capital</h2>
Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
<h3>Unraveling the Financial Story of Hercules Capital</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Hercules Capital's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -29.4% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Hercules Capital's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 54.32% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Hercules Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.73%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Hercules Capital's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.85%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Hercules Capital's debt-to-equity ratio stands notably higher than the industry average, reaching 0.99. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 5 Analysts Discuss Hercules Capital Stock

Wells Fargo analyst Timothy O'Shea maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $17 to $18.

Wells Fargo Maintains Overweight on Hercules Capital, Raises Price Target to $18

On CNBC&rsquo;s &quot;<a href="https://www.cnbc.com/video/2024/01/25/final-trades-tesla-uber-and-southern-copper.html">Halftime Report Final Trades</a>,&quot; Jenny Harrington of Gilman Hill Asset Management named Hercules Capital, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/htgc#NYSE">HTGC</a>) <a href="https://www.benzinga.com/quote/HTGC/news"> as her final trade</a>.
On Jan. 16, Compass Point analyst Casey Alexander downgraded Hercules Capital from Buy to Neutral and announced a $17.5 price target.
Jim Lebenthal of Cerity Partners named General Motors Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gm#NYSE">GM</a>), which is scheduled to release earnings this week.
GM is scheduled to report earnings on Jan. 30, 2024. Analysts expect the company to report quarterly earnings at $1.16 per share, down from $2.12 per share in the year-ago period. The company is projected to post revenue of $38.97 billion, compared to $43.11 billion in the year-earlier quarter, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Joshua Brown of Ritholtz Wealth Management picked Toast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tost#NYSE">TOST</a>).
On Jan. 10, Goldman Sachs analyst Will Nance upgraded Toast from Neutral to Buy and announced a $24 price target. During November, Toast said third-quarter revenue grew 37% year-over-year to $1.032 billion, which beat the consensus estimate of $1.03 billion, according to Benzinga Pro. The company reported a quarterly loss of 9 cents per share, which beat estimates for a <a href="https://www.benzinga.com/news/earnings/23/11/35674274/toast-shares-are-getting-burnt-wednesday-whats-going-on">loss of 10 cents per share</a>.
Bryn Talkington of Requisite Capital Management named JPMorgan Equity Premium Income ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jepi#NYSE">JEPI</a>).
<h3>Price Action</h3>
<ul>
<li>Hercules Capital shares gained 1.3% to close at $17.56.</li>
<li>GM shares rose 0.1% to close at $35.18 on Friday.</li>
<li>Toast shares gained 5.1% to settle at $17.45.</li>
<li>JPMorgan Equity Premium Income ETF rose 0.1% during Friday&rsquo;s session.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36777889/insiders-buying-compass-minerals-international-and-2-other-stocks"> Insiders Buying Compass Minerals International And 2 Other Stocks</a>
Image: Shutterstock

General Motors, Hercules Capital, Toast And More: CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Toast, JPMorgan Equity Premium Income, Hercules Capital And General Motors

KBW analyst Paul Johnson assigned a Hold rating to Hercules Capital (HTGC – Research Report) yesterday and set a price target of $19.00. The compan...

KBW Issues a Hold Rating on Hercules Capital (HTGC)

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Hercules Capital (HTGC – Research Report), Trupanio...

Analysts Conflicted on These Financial Names: Hercules Capital (HTGC), Trupanion (TRUP) and Citizens Financial (CFG)

Hercules Capital: VC-Focused Name With Less Risk And Better Return Prospects Than Average BDC

Hercules Capital: This 10% Yielding Cash Cow Is Still Worth Buying

Ares Capital's Q1 Has Important Ramifications For The BDC Sector

Barings BDC: One Of The Few Deals In The BDC Sector

X4 Pharma gains on new $125 financing

Hercules Capital: Solid 10% Yield, But Sky-High Valuation

Hercules Capital goes ex dividend Monday

Ares Capital: Building A Big-Yield Portfolio (BDCs, CEFs, REITs)